Recent Finacing
Recent Raise
Symbiomix Therapeutics develops women's health infection treatments; its lead candidate SYM-1219 (secnidazole) is a single-dose oral 5-nitroimidazole antibiotic undergoing pivotal clinical development for bacterial vaginosis with FDA QIDP designation.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors